MYCOTOPIA THERAPIES, INC. - Form 10-K/A SEC filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K/A (Amendment No. 1)

☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the fiscal year ended December 31, 2022
	or
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from _______ to _____

Commission file number: 000-56022
MYCOTOPIA THERAPIES, INC.
(Exact name of registrant as specified in its charter)
Nevada			87-0645794
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)

18851 NE 29th Ave., Suite 700, Aventura, FL 33180
(Address of principal executive offices, including zip code)

954-233-3511
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None
Title of each class		Trading Symbol(s)	Name of each exchange on which registered
N/A		N/A	N/A

Securities registered pursuant to Section 12(g) of the Act:
Common Stock, Par Value $0.001
(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes ☒ No

Indicate by check mark if the registrant is not required to file reports pursuant to the Section 13 or Section 15(d) of the Exchange Act. ☒ Yes ☐ No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
	Large accelerated filer ☐	Accelerated filer ☐
	Non-accelerated Filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting fi rm that prepared or issued its audit report ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐Yes ☒ No

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter. The aggregate market value of the voting and nonvoting common equity held by non affiliates, computed by reference to the price at which our common equity was last sold or the average bid and asked price of such common equity at June 30, 2022, was $6,232,015.

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. As of March 27, 2023, we had 14,858,357 shares of common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE: None.

EXPLANATORY NOTE

Mycotopia Therapies, Inc. (the “Company”) filed its Annual Report on Form 10-K for the year ended December 31, 2022, with the Securities and Exchange Commission (“SEC”) on March 30, 2023 (the “Original Form 10-K”). This Amendment No. 1 on Form 10-K/A (“Amendment No. 1” or “Form 10-K/A”). This Amendment No. 1 on Form 10-K/A is being filed to reflect the restatement of accrued expenses – related party, common stock, additional paid-in capital, general and administrative expenses, net loss, and net loss per share (the “Restatement”) in the consolidated balance sheet and statement of operations for the year ended December 31, 2022.

The Restatement is due to the Company performing an evaluation of its accounting in connection with the employment agreement entered into between Mycotopia Therapies, Inc. (“Mycotopia”) and Ben Kaplan, the Company’s CEO. Management determined that the Original Form 10-K does not give effect to the issuance of a warrant (the “Warrant”) to purchase shares 5% of the fully diluted common stock outstanding of Mycotopia. The cash compensation and Warrant was granted to the CEO of the Company pursuant to his consulting agreement with Mycotopia entered into on November 17, 2021. On April 25, 2023, management concluded its evaluation and determined that the identified errors require the filing of Amendment No. 1, as further discussed in Notes 1 and 4 to the consolidated financial statements included in this Form 10-K/A.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (RESTATED)

The following discussion of our financial condition and results of operations should be read in conjunction with the audited financial statements and the notes to those statements included elsewhere in this report. This discussion contains forward-looking statements that involve risks and uncertainties. You should specifically consider the various risk factors identified in this report that could cause actual results to differ materially from those anticipated in these forward-looking statements.

Results of Operations

Comparison of Years Ended December 31, 2022 and 2021

Sales and Cost of Sales

We did not have any revenue or cost of revenue from operations for the years ended December 31, 2022 and 2021.

Operating Expenses from Operations

Operating expenses from operations for the years ended December 31, 2022 and 2021, consisted of general and administrative expenses of $1,736,336 and $4,986,970, respectively. General and administrative expenses consisted primarily of consulting fees, stock-based compensation, board compensation, and legal and professional services. Our decrease in general and administrative expenses is the result of decrease administrative costs due to decreased compliance costs. The Company has employed cost savings strategies as we seek to find another active business that may be interested in acquiring us.

Other Income (Expense)

Other expense of $875,533 and $151,621 for the years ended December 31, 2022 and 2021, respectively, consisted of interest expense from convertible notes with debt discounts and interest expense from related parties.

Net Loss

We had a net loss for the years ended December 31, 2022 and 2021, of $2,611,869 and $5,138,591, respectively.

Liquidity and Capital Resources

As of December 31, 2022, we had working capital deficiency of $378,614 own from working capital of $673,149 as of December 31, 2021. Our current assets of $385,899 consisted solely of cash, while our current liabilities consisted predominantly of accrued interest, convertible notes payable, and a shareholder loan. We had an accumulated deficit of $7,779,634 as of December 31, 2022, an increase from an accumulated deficit of $5,167,765 as of December 31, 2021.

Operating activities used net cash of $656,620 for the year ended December 31, 2022, as compared to using net cash of $235,482 for the year ended December 31, 2021. Investing activities used net cash of $0 and $2,746, respectively, for the years ended December 31, 2022 and 2021. Cash used in financing activities was $225,000 for the year ended December 31, 2022, as compared to cash provided of $1,395,000 for the year ended December 31, 2021. We had a cash balance of $385,899 and $1,267,519 as of December 31, 2022 and 2021, respectively.

Our monthly operating costs averaged approximately $55,000 per month for the year ended December 31, 2022, excluding capital expenditures. We plan to fund our operations with our cash on hand and additional financing.

Our consolidated financial statements have been prepared assuming we will continue as a going concern. Our ability to continue our operations as a going concern is dependent on management’s plans, which includes successfully integrating Mycotopia Therapies, Inc. which was acquired subsequent to December 31, 2020. The accompanying

consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should we be unable to continue as a going concern.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Critical Accounting Policies

We have identified the policies outlined below as critical to our business operations and an understanding of our results of operations. The list is not intended to be a comprehensive list of all of our accounting policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by generally accepted accounting principles in the United States, with no need for management’s judgment in their application. The impact and any associated risks related to these policies on our business operations is discussed throughout Management’s Discussion and Analysis of Financial Condition and Results of Operations when such policies affect our reported and expected financial results. For a detailed discussion on the application of these and other accounting policies, see the notes to our December 31, 2022, financial statements. Note that our preparation of the financial statements requires us to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities at the date of our financial statements, and the reported amounts of revenue and expenses during the reporting period. We cannot assure that actual results will not differ from those estimates.

Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from those estimates. The Company’s estimates include the allowance for doubtful accounts and useful lives of property plant and equipment.

Depreciation of equipment is dependent upon estimates of useful lives and residual values, both of which are determined through the exercise of judgement. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that consider factors such as economic/market conditions and the useful lives of assets.

Stock Based Compensation

We follow ASC Topic 718, Compensation–Stock Compensation, which prescribes accounting and reporting standards for all share-based payment transactions in which employee and non-employee services are acquired. Share-based payments to employees and non-employees, including grants of stock options, are recognized as compensation expense in the financial statements based on their fair values on the grant date. That expense is recognized over the period required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

Recently Issued Accounting Pronouncements

Recently issued accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that require adoption and that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.

INDEX TO FINANCIAL STATEMENTS

	Page

Audited Consolidated Financial Statements for the Years
Ended December 31, 2022 and 2021:

Report of Independent Registered Public Accounting Firm (ID 6117)	7

Consolidated Balance Sheets as of December 31, 2022 and 2021	9

Consolidated Statements of Operations for the Years Ended December 31, 2022 and 2021	10

Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the Years Ended December 31, 2022 and 2021	11

Consolidated Statements of Cash Flows for the Years Ended December 31, 2022 and 2021	12

Notes to the Consolidated Financial Statements	13

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders

Mycotopia Therapies, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets Mycotopia Therapies, Inc. (the Company) as of December 31, 2022 and 2021, and the related statements of operations, changes in stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Going Concern Considerations

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has negative cashflows from operations and has not generated revenues, which raises substantial doubt about its ability to continue as a going concern. Management’s plans regarding this matter are described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Going Concern Disclosure

Critical Audit Matter Description

The consolidated financial statements of the Company are prepared on a going concern basis, which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and

discharge its liabilities in the normal course of operations. The Company’s consideration of going concern included the following:

·Acknowledgement of the Company’s history of net losses and negative working capital.

·Assessment of contractual obligations, such as commitments for repayments of accounts payable, accrued liabilities and convertible notes payable (collectively “obligations”).

·Assumptions that illustrate the Company’s ability to meet the obligations through management of expenditures, obtaining additional debt financing, and issuance of capital stock for additional funding to meet its operating needs.

How the Critical Audit Matter Was Addressed in the Audit

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included the following, among others:

·We gained an understanding of the Company’s internal controls, projections, and estimates as they relate to continuance as a going concern.

·We evaluated the probability that the Company will be able to manage expenditures, obtain debt financing, and access funding from the capital markets.

/s/ Pinnacle Accountancy Group of Utah

We have served as the Company’s auditor since 2016.

Pinnacle Accountancy Group of Utah

Farmington, Utah

March 30, 2023, except the effects of the matter described in Note 2, Note 3, Note 4, Note 6 and Note 8, which are dated November 3, 2023

Mycotopia Therapies, Inc.
CONSOLIDATED BALANCE SHEETS


	December 31,		December 31,
	2022		2021
		(Restated)
CURRENT ASSETS
Cash	$	`385,899`	$	`1,267,519`
TOTAL CURRENT ASSETS		`385,899`		`1,267,519`

NON-CURRENT ASSETS
Property and equipment, net		`1,496`		`2,497`
TOTAL ASSETS	$	`387,395`	$	`1,270,016`

LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT)

CURRENT LIABILITIES
Accounts payable and accrued expenses	$	`335,590`	$	`121,031`
Accrued expenses - related party		`288,000`		`338,000`
Accrued interest - shareholder loan		`-`		`10,339`
Shareholder loan		`-`		`125,000`
Convertible Note Payable, net of debt discount		`140,923`		`-`
TOTAL CURRENT LIABILITES		`764,513`		`594,370`

Convertible Note Payable, net of debt discount		`514,230`		`123,625`
Shareholder loan payable, non-current		`-`		`500,000`
TOTAL LIABILITIES		`1,278,743`		`1,217,995`

MEZZANINE EQUITY
Preferred stock, $0.001 par value; 5,000,000 shares authorized, and 0 and 0, as of December 31, 2022 and December 31, 2021; liquidation preference of 0 and $0, respectively		`-`		`-`

STOCKHOLDERS' EQUITY (DEFICIT)
Common stock, $0.001 par value, 100,000,000 shares authorized; 14,858,357 and 13,967,332, shares issued and outstanding, respectively.		`14,857`		`13,966`
Additional paid-in capital		`6,873,429`		`5,205,820`
Accumulated deficit		`(7,779,634)`		`(5,167,765)`

TOTAL STOCKHOLDERS' EQUITY (DEFICIT)		`(891,348)`		`52,021`

TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT)	$	`387,395`	$	`1,270,016`

Mycotopia Therapies, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS


	For the Year
	Ended December 31,
	2022		2021
		(Restated)
OPERATING EXPENSE
General and administrative	$	1,736,336	$	4,986,970
TOTAL OPERATING EXPENSES		1,736,336		4,986,970

NET LOSS FROM OPERATIONS		(1,736,336)		(4,986,970)

OTHER (EXPENSE) INCOME
Interest expense		(868,330)		(143,057)
Interest expense - related party		(7,203)		(8,564)
TOTAL OTHER (EXPENSE) INCOME		(875,533)		(151,621)

NET LOSS BEFORE PROVISION FOR INCOME TAXES	$	(2,611,869)	$	(5,138,591)
Provision for income taxes		-		-

NET LOSS	$	(2,611,869)	$	(5,138,591)

NET LOSS PER SHARE – BASIC AND DILUTED	$	(0.18)	$	(0.38)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – BASIC AND DILUTED		14,445,002		13,412,634

MYCOTOPIA THERAPIES, INC.

CONSOLIDATED STATEMENT OF MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT)

Preferred Shares

Common Stock

Additional

Accumulated

Shares

Amount

Shares

Amount

Paid-In Capital

Deficit

Total

Balance as of December 31 , 2020

-

$-

12,925,420

$12,925

-

$(29,174)

$(16,249)

Stock issued for services

1,016,912

1,016

4,310,845

-

4,311,861

Debt discount on convertible debt and warrants

25,000

25

894,975

895,000

Net loss for the year ended, December 31, 2021

(5,138,591)

Balance as of December 31 , 2021

-

13,967,332

13,966

5,205,820

(5,167,765)

52,021

Stock based compensation (restated)

-

322,122

322

1,022,533

-

1,022,855

Sale of preferred shares in private placements

15,000

150,000

-

150,000

Conversion of preferred shares to common shares

(15,000)

(150,000)

105,834

106

149,894

-

Debt discount on convertible debt and warrants

-

250,000

-

250,000

Conversion of convertible debt into shares of common stock

-

245,645

246

245,399

-

245,645

Common stock issued on cashless exercise of warrant

-

217,424

217

(217)

-

Net loss for the year ended, December 31, 2022 (restated)

-

$(2,611,869)

(2,611,869)

Balance as of December 31, 2022 (restated)

-

$-

14,858,357

$14,857

$6,873,429

$(7,779,634)

$(891,348)

The accompanying notes are an integral part of these consolidated financial statements

Mycotopia Therapies, Inc.
CONSOLIDATED STATEMENTS OF CASH FLOWS


		For the Year Ended, December 31,
		2022		2021
		(as restated)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	`(2,611,869)`	$	`(5,138,591)`
Adjustments to Reconcile Net Loss to Net Cash Used In Operating Activities:
Depreciation expense		`1,001`		`249`
Amortization of debt discount		`764,028`		`123,625`
Stock based compensation		`1,022,855`		`4,311,861`
Changes in Operating Assets and Liabilities:
Increase in accounts payable and accrued expenses		`227,704`		`408,811`
Increase (Decrease) in accrued expenses - related party		`(50,000)`		`50,000`
Increase (Decrease) in accrued interest - shareholder loan		`(10,339)`		`8,563`
NET CASH USED IN OPERATING ACTIVITES		`(656,620)`		`(235,482)`

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		`-`		`(2,746)`
NET CASH USED IN INVESTING ACTIVITIES		`-`		`(2,746)`

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from shareholder loan		`-`		`500,000`
Repayment of shareholder loan		`(625,000)`		`-`
Proceeds from the issuance of preferred stock		`150,000`		`-`
Proceeds from the issuance of convertible debt		`250,000`		`895,000`
NET CASH PROVIDED (USED) BY FINANCING ACTIVITES		`(225,000)`		`1,395,000`


NET CHANGE IN CASH		`(881,620)`		`1,156,772`
CASH AT BEGINNING OF PERIOD		`1,267,519`		`110,747`
CASH AT END OF PERIOD	$	`385,899`	$	`1,267,519`

Cash paid during the period:
Cash paid for interest	$	`17,542`	$	`-`
Cash paid for income taxes	$	`-`	$	`-`

Supplemental Disclosure of Non-Cash Financing Activities:
Conversion of preferred to common stock	$	`150,000`	$	`-`
Debt discount on convertible note payable	$	`250,000`	$	`895,000`
Conversion of convertible debt and interest	$	`245,645`	$	`-`

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

Organization and Business Activity

The Company was incorporated in Nevada on January 21, 2000, under the name RM Investors, Inc. In December 2020, we entered into definitive agreements with Ehave, Inc., an Ontario corporation (“Ehave”), Mycotopia Therapies Inc., a Florida corporation and wholly owned subsidiary of Ehave (“MYC”), and the former and current directors of 20/20 Global that provide for: (i) 20/20 Global’s purchase for $350,000 in cash of all of the outstanding stock of MYC from Ehave under a Stock Purchase Agreement, resulting in MYC becoming a wholly owned subsidiary of 20/20 Global; and (ii) the change of control of 20/20 Global’s board of directors and management under a Change of Control and Funding Agreement. In a related transaction, Ehave agreed to purchase 9,793,754 shares of 20/20 Global common stock, which constitute approximately 75.77% of the then-issued and outstanding shares of 20/20 Global’s common stock, for $350,000 in cash through a Stock Purchase Agreement (“MYC SPA”) with 20/20 Global stockholders Mark D. Williams, Colin Gibson, and The Robert and Joanna Williams Trust. Ehave’s ownership has since been diluted to 65.9% as of December 31, 2022.

On January 19, 2021, the above transaction closed. Because the former shareholder of Mycotopia Therapies, Inc. acquired 75.77% of the Company’s then-outstanding stock and there was a change in control of the board of directors, the transaction was accounted for as a reverse merger in which Mycotopia Therapies, Inc. was deemed to be the accounting acquirer and the Company the legal acquirer. Subsequent to the transaction, the Company changed its name from 20/20 Global, Inc. to Mycotopia Therapies, Inc.

As a result of the transaction, the historical consolidated financial statements of the Company for periods prior to the date of the transaction are those of Mycotopia Therapies, Inc., as the accounting acquirer, and all references to the consolidated financial statements of the Company apply to the historical financial statements of Mycotopia Therapies, Inc. prior to the transaction and the consolidated financial statements of the Company subsequent to the transaction.

NOTE 2 - GOING CONCERN

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. To date, the Company has generated no revenues, experienced negative operating cash flows and has incurred operating losses since inception. Management expects the Company to continue to fund its operations primarily through the issuance of debt or equity.

For the year ended December 31, 2022, the Company incurred a net loss of $2,611,869, had negative cash flows from operations of $656,620 and may incur additional future losses. At December 31, 2022, the Company had total current assets of $385,899 and total current liabilities of $764,513 resulting in working capital deficit of $378,614.

The Company’s existence is dependent upon management’s ability to develop profitable operations. Management is devoting substantially all of its efforts to developing its business and raising capital and there can be no assurance that the Company’s efforts will be successful. No assurance can be given that management’s actions will result in profitable operations or the resolution of its liquidity problems. The accompanying consolidated financial statements do not include any adjustments that might result should the company be unable to continue as a going concern.

In order to improve the Company’s liquidity, the Company’s management is actively pursuing additional equity financing through discussions with investment bankers and private investors. There can be no assurance that the Company will be successful in its effort to secure additional equity financing.

The financial statements do not include any adjustments relating to the recoverability of assets and the amount or classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Restatement of Previously Issued Financial Statements

Subsequent to the Company’s filing of its Annual Report on Form 10-K for the year ended December 31, 2022, with the Securities and Exchange Commission on March 30, 2023, the Company performed an evaluation of its accounting

in connection with the employment agreement entered into between Mycotopia and Ben Kaplan, the Company’s CEO. Management determined that the Original Form 10-K does not give effect to the issuance of a warrant (the “Warrant”) to purchase shares 5% of the fully diluted common stock outstanding of Mycotopia. The Warrant was granted to the Chief Executive Officer of the Company pursuant to his consulting agreement (the “Consulting Agreement”) with Mycotopia entered into on November 17, 2021. Management concluded on April 25, 2023 that it has identified errors in its calculation of compensation in relation to the Consulting Agreement. Accordingly, the Company has restated its consolidated financial statements in this Form 10-K/A as outlined further below and in Note 4 - Related Party Transactions.

For the Year Ended December 31, 2022

The following table sets forth the effects of the adjustments on affected items within the Company’s previously reported consolidated balance sheets for the year ended December 31, 2022, and includes a reclass from accounts payable and accrued expenses to accrued expenses – related party of $288,000, an increase to additional paid-in capital of $2,178,278, and an increase to accumulated deficit of $2,178,278.

Additionally, please refer to Note 4 – Related Party Transactions, where the Company has included additional disclosure related to the CEO’s consulting agreement with the Company.

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASUs, of the Financial Accounting Standards Board, or FASB.

Basis of Consolidation

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, MYC. All inter-company accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Our financial statements include, when applicable, disclosures of estimates, assumptions, uncertainties, and markets that could affect our financial statements and future operations.

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.

Fixed Assets and Depreciation

Property, plant, and equipment are stated at cost. For financial reporting, we provide for depreciation using the straight-line method at rates based upon the estimated useful lives of the various assets. Depreciation expense was $1,001 and $249 for the years ended December 31, 2022 and 2021, respectively. The estimated useful lives are as follows: buildings and improvements—30 years; machinery and equipment—10-15 years; computer software—3-5 years; vehicles—3-7 years; and land improvements—10-20 years. We assess our long-lived assets for impairment whenever there is an indicator of impairment. Impairment losses are evaluated if the estimated undiscounted cash flows from using the assets are less than carrying value. A loss is recognized when the carrying value of an asset exceeds its fair value. There were no impairment losses in 2022 and 2021.

Fair Value of Financial Instruments

The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:

Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2 – Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data; Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

There were no changes in the fair value hierarchy leveling during the years ended December 31, 2022 and 2021.

Income Taxes

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2022 and 2021, the Company had a full valuation allowance against its deferred tax assets.

We adopted ASC 740-10-25, Income Taxes—Recognition, which addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10-25, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. ASC 740-10-25 also provides guidance on derecognition, classification, interest and penalties on income taxes, and accounting in interim periods and requires increased disclosures. We had no material adjustments to our liabilities for unrecognized income tax benefits according to the provisions of ASC 740-10-25.

Stock Based Compensation

We follow ASC 718, Compensation–Stock Compensation, which prescribes accounting and reporting standards for all share-based payment transactions in which employee and non-employee services are acquired. Share-based payments to employees and non-employees, including grants of stock options, are recognized as compensation expense in the financial statements based on their fair values on the grant date. That expense is recognized over the period required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

Basic and Diluted Net Loss per Share (Restated)

Basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period before giving effect to stock options, stock warrants, restricted stock units and convertible securities outstanding, which are considered to be dilutive common stock equivalents. Diluted net loss per common share is calculated based on the weighted average number of common and potentially dilutive shares outstanding during the period after giving effect to dilutive common stock equivalents. Contingently issuable shares are included in the computation of basic loss per share when issuance of the shares is no longer contingent. The common stock equivalents not included in the computation of earnings per share because the effect was antidilutive, were related to convertible debt and totaled 1,210,590 and 1,027,087 for the years ended December 31, 2022 and 2021, respectively, and the outstanding warrants that totaled 1,542,502 and 1,463,784 for the years ended December 31, 2022 and 2021, respectively.

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying consolidated financial statements, other than those disclosed below.

In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40)” (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASU’s amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact ASU 2020-06 will have on its financial statements.

NOTE 4 – RELATED PARTY TRANSACTIONS (RESTATED)

During the year ended December 31, 2020, the Company entered into two term promissory notes with Ehave, Inc. (a majority shareholder) in the amount of $125,000. During the year ended December 31, 2021, the Company entered a term promissory note with Ehave, Inc. in the amount of $500,000. The notes mature two years after the issuance date and bear an interest rate of 1.75% per year. During the year ended December 31, 2022, the Company repaid the $625,000 in outstanding principal and interest due on the three promissory notes. As of December 31, 2022 and 2021, the Company owes $0 and $625,000, respectively. As of December 31, 2022 and 2021, the Company accrued interest related to these loans and has outstanding $0 and $10,339, respectively. During the year ended December 31, 2022 and 2021, the Company recorded interest expense of $7,203 and $8,564, respectively, in relation to these notes.

Mycotopia Consulting Agreement with the CEO

On November 17, 2021, Mycotopia entered into an Executive Consulting Agreement (the “Mycotopia Consulting Agreement”), with Benjamin Kaplan (“BK”) to serve as the Company’s CEO for an initial term of 36 months. As of December 31, 2022, the Company has recorded $288,000 for cash compensation as accrued expense - related party in relation to the Mycotopia Consulting Agreement. During the years ended December 31, 2022 and 2021, the Company recorded $436,417 and $2,317,861, respectively, as general and administrative expense, of which $148,417 and $2,029,861, respectively, was recorded as stock-based compensation in relation to the Warrants issued, in connection with the Mycotopia Consulting Agreement.

Significant terms of the Mycotopia Consulting Agreement are as follows:

BK was granted a Warrant to purchase that number of shares of Mycotopia common stock equal to 5% of the issued and outstanding Mycotopia common shares, on a fully diluted basis. The Warrant has an exercise price of $0.01 per share and shall expire November 16, 2023.

During the years ended December 31, 2022 and 2021, the Company issued 63,718 and 812,118, respectively, vested Mycotopia warrant shares in accordance with the Warrant valued at $148,417 and 2,029,861, respectively (see Note 6).

Bonus

The Company will pay the CEO a bonus in Mycotopia restricted stock or restricted stock units based on the following EBITDA milestones. As of September 30, 2022, no EBITDA milestones were met, and no amounts have been recorded for the bonus milestones.

		December 31, 2022			December 31, 2021
	Maturity Date	Total Outstanding***	Principal	Interest	Total Outstanding***	Principal	Interest

*Lender A*	8/27/2023	$ 556,244	$ 500,000	$ 56,244	$ 513,883	$ 500,000	$ 13,883
*Lender B*	9/27/2023	60,907	55,000	5,907	56,268.91	55,000	1,269
*Lender C*	10/27/2023	241,528	220,000	21,528	223,134	220,000	3,134
*Lender D*	11/9/2023	-	-	-	27,813	27,500	313
*Lender E*	10/21/2023	2,407	-	2,407	55,856	55,000	856
*Lender F*	12/27/2023	-	-	-	150,132	150,000	132
*Lender G*	1/21/2024	349,504	325,000	24,504	-	-	-
		$ 1,210,590	$ 1,100,000	$ 110,590	$ 1,027,087	$ 1,007,500	$ 19,587

		*** - Total Outstanding = Principal + Interest as of December 31, 2022 and December 31, 2021

During the years ended December 31, 2022 and 2021, the Company recorded an aggregate debt discount of $325,000 and $1,007,500, respectively, under the terms of convertible promissory note agreement. The total $325,000 debt discount was allocated between the original issue discount related to cash financing fees of $75,000, as well as $250,000 recorded as an offset to additional paid-in capital in connection with the beneficial conversion feature and warrants (see Note 6).

During the years ended December 31, 2022 and 2021, the Company recorded debt discount amortization expense in the amount of $764,028 and $123,625, respectively. As of December 31, 2022, the Company had an unamortized debt discount balance of $444,850 with a weighted amortization period of 1.24 years.

The Company recorded $250,000 as a debt discount with an offset to additional paid-in capital in relation to the warrants issued in connection with the debt.

NOTE 6 – STOCKHOLDERS’ EQUITY (RESTATED)

We are authorized to issue 100,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. Each share of common stock entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought.

Mezzanine Equity

The Preferred Shares are recorded as mezzanine equity in accordance with ASC 480, “Distinguishing Liabilities from Equity,” at its initial net carrying value in the amount of $50,000. The Series A Shares are recorded as mezzanine equity in accordance with ASC 480 because the Company may be obligated to issue a variable number of shares at a fixed price known at inception and there is no maximum number of shares that could potentially be issued upon conversion. In this instance, cash settlement would be presumed and the Series A Shares are classified as mezzanine equity in accordance with ASC 480-10-S99. Immediately upon effectiveness of the registration statement registering for resale of all the common stock issuable under the Series A Shares, all outstanding Series A Shares shall automatically convert into common stock.

During the year ended December 31, 2022, the Company sold 15,000 shares of preferred stock to three shareholders for $150,000 in proceeds as part under a Regulation A offering of Section 3(6) of the Securities Act of 1933. The shares are allowed to convert into common stock by option of the holder at any time based on the fair market value of the common stock at the date of the conversion. As of December 31, 2022, 15,000 preferred shares with a fair value of $150,000 were converted in various installments, into an aggregate 105,834 shares of common stock.

Conversion of Convertible Debt and Warrants to Equity

During year ended December 31, 2022, the Company issued 245,645 shares of common stock, in the aggregate, upon the conversion of convertible promissory notes and accrued interest in the amount of $245,645 (see Note 5).

STOCK BASED COMPENSATION

On July 26, 2021, the Company issued 1,000,000 shares of common stock to three consultants for services rendered. The Company expensed $2,252,000 in relation to this issuance which was the grant date fair value.

On July 27, 2021 and October 12, 2021, the Company issued 7,537 and 9,375, respectively, shares of common stock to a board member for board services rendered. The Company expensed $30,000, in the aggregate, in relation to this issuance which was the grant date fair value.

On January 21, 2022, the Company issued 250,000 shares of common stock to a related party and majority shareholder, Benjamin Kaplan, as part of his compensation for services rendered in accordance with his Agreement (Note 7) for services rendered as CEO. The Company expensed $750,000 in relation to this issuance.

On January 24, 2022, the Company issued 12,500 shares of common stock to a consultant for services rendered. The Company expensed $38,188 in relation to this issuance.

On March 17, 2022, the Company issued 59,622 shares of common stock valued at $86,250 as stock-based compensation for consulting services rendered.

Warrants Issued

During the year ended December 31, 2022, the Company issued 325,000 warrants, to purchase common stock as part of the convertible promissory notes discussed above in Note 5.

During the year ended December 31, 2022, the Company issued 217,424 shares of common stock upon the cashless exercise of 151,667 warrants.

The following table reflects a summary of Common Stock warrants outstanding and warrant activity during the period ended December 31, 2022

The intrinsic value of warrants outstanding as of December 31, 2022 was approximately $149,000.

All the warrants granted during the year ending December 31, 2022 were valued using the Black-Scholes option pricing model using the following weighted average assumptions:

	For the Year Ended December 31, 2022
Expected term, in years		1.86
Exercise price		$1.09
Expected volatility		170%
Stock price		2.82
Risk-free interest rate		1.47%
Dividend yield		0%

NOTE 7 – COMMITMENTS AND CONTINGENCIES

On November 17, 2021, the Company entered into an Executive Consulting Agreement (the “Agreement”) with Benjamin Kaplan (“Kaplan”) whereby Kaplan was appointed as CEO of the Company. We hired Kaplan for an initial term of thirty-six (36) months subject to certain termination provisions, whereby the Agreement will automatically renew for an additional twelve (12) month period. We shall pay Kaplan in the following manner: (i) A consulting fee of $24,000 per month for services performed for a total compensation of $288,000 payable for each twelve (12) month period, (ii) Bonus compensation milestones by offering Kaplan a Warrant to purchase that number of shares of common stock of the Company equal to 5% of the issued and outstanding common shares, on a fully diluted basis, (iii) A significant transaction stock grant whereby Kaplan shall be granted that number of shares of common stock or a new series of preferred shares of the Company, that is convertible into common stock of the Company equal to 5% of the value of all of the consideration, including any stock, cash, or debt, of such completed transaction. As of December 31, 2022 and 2021, the Company accrued $288,000 and $50,000, respectively, related to the Agreement.

During 2022, the Company entered into an agreement with Dr. Muneer Ali as an advisor for the Medical Advisory Board. The Company shall grant the advisor an annual fee of $35,000 payable in shares of common stock.

NOTE 8 – INCOME TAXES (RESTATED)

The provision for federal and state income taxes is associated with and included in net income from discontinued operations and consists of the following components:

	2022		2021
Current Income taxes	$		$
Federal		-		-
State		-		-
Total current income tax expenses	$	-	$	-

Deferred income taxes
Federal	$	-	$	-
State		-		-
Total current income tax expenses	$	-	$	-

Total income tax expense	$	-	$	-

The reconciliation between income taxes at the U.S. federal and state statutory rates of approximately 25.5% and the amount recorded in the accompanying consolidated financial statements is as follows:

	As Reported	Reclass	Adjustment	As Restated
Accounts payable and accrued expenses	`$623,590`	`$(288,000)`	`-`	`$335,590`
Accrued expenses – related party	`-`	`$288,000`	`-`	`$288,000`
Additional paid-in capital	`$4,695,151`	`-`	`$2,178,278`	`$6,873,429`
Accumulated deficit	`$(5,601,356)`	`-`	`$(2,178,278)`	`$(7,779,634)`

	As Reported		Adjustment		As Restated
General and administrative		`$1,875,919`		`$(139,583)`		`$1,736,336`
Total operating expenses		`$1,875,919`		`$(139,583)`		`$1,736,336`
Loss from operations		`$(1,875,919)`		`$139,583`		`$(1,736,336)`
Net loss before provision from income taxes		`$(2,751,452)`		`$139,583`		`$(2,611,869)`
Net loss		`$(2,751,452)`		`$139,583`		`$(2,611,869)`
Basic and diluted loss per share		`$(0.19)`		`$0.01`		`$(0.18)`

	Underlying Shares			Weighted Average Exercise Price		Weighted Average Term (Years)
Warrants outstanding at January 1, 2022		1,463,784	$		$0.67		1.83
Granted		230,385			1.09		1.86
Exercised		(151,667)
Forfeited		-
Warrants outstanding and exercisable at December 31, 2022		1,542,502			$ 0.65		1.29

	2022		2021
Tax expense at U.S. federal statutory rate	$	(548,492)	$	(1,079,014)
Tax expense at state statutory rate		(42,294)		(123,863)
Stock Based Compensation		183,632		479,220
Amortization of Debt Discount		160,446		25,961
Change in valuation allowance		246,709		722,509
Other		-		(24,723)
Total	$	-	$	-

	2022		2021
Federal net operating loss carryforward	$	207,058	$	601,639
State net operating loss carryforward		42,841		124,482
Total Deferred tax assets	$	249,899	$	726,121
Valuation allowance		(249,899)		(726,121)
	$	-	$	-

Bonus		EBITDA Milestones
$	100,000	1st $1,000,000
$	100,000	2nd $1,000,000
$	100,000	3rd $1,000,000
$	100,000	4th $1,000,000
$	100,000	5th $1,000,000

Bonus (Shares)	Market Capitalization Milestone
250,000	$	30,000,000
250,000	$	40,000,000
250,000	$	60,000,000
250,000	$	80,000,000
250,000	$	100,000,000